Expression of matrix metalloproteinases in exosomes in sarcopenia and sarcopenic obesity

The study of plasma levels of matrix metalloproteinases (MMPs) and their inhibitor (TIMP-1) in patients with sarcopenia of varying severity, taking into account metabolic disorders and sarcopenic obesity has been conducted. In this study, sarcopenia was accompanied by sarcopenic obesity in 75% of cases. The level of the total MMP2 pool in extracellular vesicles was increased in the group of patients with isolated sarcopenia (p<0.05), whereas in patients with sarcopenic obesity, the concentration of the total MMP2 pool remained stable. Furthermore, the level of MMP2+9+TIMP- was elevated in patients with presarcopenia. As the disease progressed, the content of MMP2+9+TIMP- in exosomes decreased in the group of patients with sarcopenic obesity. In the sarcopenic obesity subgroup, patients showed a statistically significant increase in C-peptide levels (p=0.01). It was found that obesity and hyperglycemia associated with insulin resistance influence the redistribution of matrix metalloproteinases. Specifically, a decrease in the level of MMP9+2+TIMP- exosomes was revealed during the transition from presarcopenia to sarcopenia in patients with sarcopenic obesity.

1. Cho M.R., Lee S., Song S.K. A Review of Sarcopenia Pathophysiology, Diagnosis, Treatment and Future Direction. Journal of Korean medical science. 2022; 37(18): e146. doi: 10.3346/jkms.2022.37. Art. e146.

2. Damluji A.A., Alfaraidhy M., AlHajri N., et al. Sarcopenia and Cardiovascular Diseases. Circulation. 2023; 147(20): 1534-1553. doi: 10.1161/CIRCULATIONAHA.123.064071.

3. Yuan S., Larsson S.C. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism: clinical and experimental. 2023; 144: Art. 155533.

4. Hou Y., Xiang J., Wang B., et al. Pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with type 2 diabetes mellitus. Frontiers in endocrinology. 2023; 14: Art. 1263650. doi: 10.3389/fendo.2023.1263650.

5. Picca A, Calvani R. Molecular Mechanism and Pathogenesis of Sarcopenia: An Overview. International journal of molecular sciences. 2021; 22(6): Art. 3032. doi: 10.3390/ijms22063032.

6. Tandon P., Montano-Loza A.J., Lai J.C., et al. Sarcopenia and frailty in decompensated cirrhosis. Journal of hepatology. 2021; 75(1): S147-S162. doi: 10.1016/j.jhep.2021.01.025.

7. Chandrasekaran P., Weiskirchen R. The Role of Obesity in Type 2 Diabetes Mellitus-An Overview. International journal of molecular sciences. 2024; 25(3): Art. 1882. doi: 10.3390/ijms25031882.

8. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. American journal of physiology. Cell physiology. 2021; 320(3): C375-C391. doi: 10.1152/ajpcell.00379.2020.

9. Schleh M.W., Caslin H.L., Garcia J.N., et al. Metaflammation in obesity and its therapeutic targeting. Science translational medicine. 2023; 15(723): Art. eadf9382. doi: 10.1126/scitranslmed.adf9382.

10. Ruze R., Liu T., Zou X., et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Frontiers in endocrinology. 2023; 14: Art. 1161521. doi: 10.3389/fendo.2023.1161521.

11. Bilski J., Pierzchalski P., Szczepanik M., et al. Multifactorial Mechanism of Sarcopenia and Sarcopenic Obesity. Role of Physical Exercise, Microbiota and Myokines. Cells. 2022; 11(1): Art. 160. doi: 10.3390/cells11010160.

12. Dowling L., Duseja A., Vilaca T., et al. MicroRNAs in obesity, sarcopenia, and commonalities for sarcopenic obesity: a systematic review. Journal of cachexia, sarcopenia and muscle. 2022; 13(1): 68-85. doi: 10.1002/jcsm.12878.

13. Wiedmer P., Jung T., Castro J.P., et al. Sarcopenia - Molecular mechanisms and open questions. Ageing research reviews. 2021; 65: Art. 101200. doi: 10.1016/j.arr.2020.101200.

14. Wei S., Nguyen T.T., Zhang Y., et al. Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Frontiers in endocrinology. 2023; 14: Art. 1185221. doi: 10.3389/fendo.2023.1185221.

15. Esmaeili F., Abolhasani M., Zabihi-Mahmoudabadi H., et al. Exosomes isolated from metabolically unhealthy normal weight and overweight phenotypes deteriorate the ER/PR positive breast cancer behavior. Journal of diabetes and metabolic disorders. 2023; 23(1): 533-544. doi: 10.1007/s40200-023-01295-1.

16. Jiang H., Li H. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021; 21(1): Art. 149. doi: 10.1186/s12885-021-07860-2.

17. Justo B.L., Jasiulionis M.G. Characteristics of TIMP1, CD63, and β1-Integrin and the Functional Impact of Their Interaction in Cancer. International journal of molecular sciences. 2021; 22(17): Art. 9319. doi: 10.3390/ijms22179319.

18. Драпкина О.М., Будневский А.В., Овсянников Е.С. и др. Саркопеническое ожирение: закономерности и парадоксы. Профилактическая медицина. 2021; 24(1): 73-78. doi: 10.17116/profmed20212401173. / Drapkina O.M., Budnevsky A.V., Ovsyannikov E.S., et al. Sarcopenic obesity: patterns and paradoxes. Russian Journal of Preventive Medicine. 2021; 24(1): 73-78 (In Russian).

19. Welsh J.A., Goberdhan D.C.I., O'Driscoll L. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles. 2024; 13(2): Art. e12404.

20. Asthana P., Wong H.L.X. Preventing obesity, insulin resistance and type 2 diabetes by targeting MT1-MMP. Biochimica et biophysica acta. Molecular basis of disease. 2024; 1870(4): Art. 167081. doi: 10.1016/j.bbadis.2024.167081.

21. Самойлова Ю.Г., Матвеева М.В., Хорошунова Е.А. и др. Композиционный состав тела при саркопении у лиц среднего возраста. Терапевтический архив. 2022; 94(10): 1149- 1154 / Samoilova I.G., Matveeva M.V., Khoroshunova E.A., et al. Body composition in sarcopenia in middle-aged individuals. Clinical therapeutics. 2022; 94(10): 1149-1154 (In Russian). doi: 10.26442/00403660.2022.10.201878.